Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail.
Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail. In nonfederal cases, state and county governments pay for healthcare during the period people are incarcerated. But once they are released, there is often a gap before they get signed up for coverage by Medicaid or another payer. For people with chronic health conditions, that gap can lead to medical conditions getting out of control and acute episodes that lead to hospitalization or premature death.
The federal Medicaid Reentry Act of 2021 is designed to remedy the situation. Currently, Medicaid programs are explicitly prohibited from covering incarcerated individuals. The proposed law would permit Medicaid to cover people starting 30 days before they are to be released. Advocates and public health officials say that would mean a smoother transition and increase the chances that recently incarcerated people will receive the medical services they need.
But the Reentry Act could have some unintended consequences. Utsha Khatri, M.D., of the Institute for Heath Equity Research at the Icahn School of Medicine at Mount Sinai in New York and Tyler N.A. Winkelman, M.D., M.Sc., of the Health, Homelessness, and Criminal Justice Lab at the Hennepin Healthcare Research Institute in Minneapolis outlined a few of the consequences in an opinion piece published in April in the New England Journal of Medicine.
Would prisons and jails put off medical care until the 30-day period before release so the cost would fall on a Medicaid program? Would care be substandard? New quality improvements might need to be developed and supported. And the Reentry Act may have little, if any, effect on coverage in the 12 states that haven’t expanded Medicaid, they noted. There are also practical problems of implementing coverage and working with prison and jail officials.
Many people in jail are awaiting trial, incarcerated because they couldn’t afford bail or were denied it. Khatri and Winkelman said they agree with the National Association of Counties and the National Sheriffs’ Association that the Reentry Act should be amended so the ban on Medicaid coverage for incarcerated people would not extend to people in jail who are awaiting trial. They also noted the Reentry Act wouldn’t deal with the larger issue of the harms done by mass incarceration.
In their view, the Reentry Act should be “coupled with broader policies redirecting people away from the harmful carceral system.” In 2021, the Reentry Act was attached to the sweeping Build Back Better legislation that passed in the House but stalled in the Senate. Khatri and Winkelman said Congress may consider the Reentry Act as a separate piece of legislation this year.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More